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Background/Aims: Di f f u s e  l a r ge  B- c e l l  l y mphoma  ( DLBCL )  i n Kor e a ns  i s  f r e que n t l y  accompanied  by  extranodal  (EN) 
disease  at  the  time  of  autologous  stem  cell  transplantation  (ASCT).  We  sought  to  determine  whether  high  EN 
involvement  affected  survival  following  ASCT  in  Koreans.
Methods: We reviewed 27 patients who had DLBCL with residual disease at ASCT: 13 with residual disease at nodal 
s i t e ( s )  o n l y  a n d  1 4  w i t h  n o d a l  a n d  E N  d i s e a s e .  
Results:  Univariate  analysis  showed  that  disease  status,  lactate  dehydrogenase  (LDH),  and  performance  status  at 
ASCT were predictors of survival following ASCT. The number of EN sites, as categorized by the International Prognostic 
Index system, had no prognostic significance. When EN involvement at ASCT was classified as negative or positive, the 
2-year overall survival for the negative group was 64%, significantly better than the 14% for the positive group (p=0.021), 
and  the  event-free  survival  for  the  negative  group  was  62%,  sign i f i c a n t l y  b e t t e r  t h a n  t h e  1 4 %  f o r  t h e  p o s i t i v e  g r o u p  
(p=0.02).
Conclusions:  Patients  who  had  DLBCL  with  residual  EN  involvement  at  ASCT  showed  worse o u t c o m e s  f o l l o w i n g  
A S C T  c o m p a r e d  t o  t h o s e  w i t h o u t  E N  d i s e a s e .
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INTRODUCTION
Non-Hodgkin’s lymphoma (NHL) was the first tumor type to 
which  high-dose  therapy,  supported  by  the  reinfusion  of 
autologous  stem  cells,  was  applied
1),  and  dose  intensification 
was  shown  to  be  able  to  cure  some  patients  with  relapsing  or 
refractory  disease
2, 3).  At  present,  NHL  is  the  second  most 
frequent  indication  for  autologous  stem  cell  transplantation 
(ASCT) because ASCT has been found to provide an increasing 
number of patients having the disease with the best opportunity 
for cure under certain circumstances. Despite recent therapeutic 
advances, however, many patients with NHL relapse after ASCT. 
Among  the  factors  having  significance  in  predicting  how  well 
patients will do after ASCT, the most predictive is the sensitivity 
of the lymphoma to chemotherapy
4-8). Factors associated with a 
poor  outcome  include  elevated  lactate  dehydrogenase  (LDH)
6), 
extensive  previous  treatment
9),  bulky  disease
10),  poor  performance 
status
11),  and  high-grade  histology
9, 12).
The  International  Prognostic  Index  (IPI)  is  a  well  established 
s c o r i n g  s y s t e m  t h a t  p r e d i c t s  t h e  s u r v i v a l  o f  p a t i e n t s  w i t h  
aggressive  NHL
13).  IPI  has  also  been  evaluated  in  patients  with 
NHL treated with high-dose therapy and ASCT
14-19). Studies that 
have assessed the value of IPI for the result of ASCT in patients 
with selected pathologic subtypes typically use the age-adjusted 
IPI  (AAIPI),  rather  than  the  IPI.  The  AAIPI  lacks  factors  for 
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two-thirds of patients who have NHL also have EN involvement 
at  initial  presentation
20)  and  over  50%  of  patients  have  residual 
EN  disease  at  ASCT
21).  W e  t h e r e f o r e  h y p o t h e s i z e d  t h a t  E N  
involvement  in  NHL  may  affect  survival  after  ASCT  in  Korean 
patients. We now report a Korean single institution study of 27 
patients  with  diffuse  large  B-cell  lymphoma  (DLBCL)  who  had 
radiologically  documented  residual  lymphoma  at  the  time  of 
high-dose  therapy  with  ASCT.
MATERIALS AND METHODS
Patients
A registry showed that 27 patients with DLBCL and residual 
disease had been treated with ASCT at the Asan Medical Center 
between  March  1996  and  May  2005.  Residual  disease  of  at 
least 1x1 cm was documented by CT scan, performed just prior 
to  high-dose  therapy.  Each  residual  EN  involvement  was 
documented  by  pathologic  examination.  Disease  status  was 
assessed  by  CT  of  the  neck,  chest,  abdomen,  and  pelvis, 
performed just prior to high-dose therapy. Bone marrow biopsies 
were  repeated  to  evaluate  the  lymphoma  status.  All  patients 
were staged, according to the Ann Arbor system. Response was 
assessed  using  the  International  Working  Group  criteria
22). 
Disease  status of  eligible  patients was  classified as  initial  partial 
response, chemotherapy-sensitive relapse, and primary refractory 
disease.  Primary  refractory  disease  was  defined  as  stable  or 
progressive  disease  documented  at  restaging,  immediately  after 
the  completion  of  induction  therapy
23).  To  be  eligible  for  ASCT, 
patients  had  to  be  15-65  years  old  and  have  biopsy-proven 
DLBCL;  adequate  hepatic,  renal,  pulmonary,  and  cardiac 
function;  negative  serology  for  human  immunodeficiency  virus; 
and no  history  of other  malignancies or  central  nervous system 
involvement. 
All  histological  specimens  were  reviewed  by  one  pathologist 
(JH).  Before  1998,  histopathological  results  had  been  classified 
according  to  the  International  Working  Formulation
24),  but  we 
retrospectively  reclassified  such  specimens  according  to  the 
World  Health  Organization/Revised  European-American  Lymp-
homa (WHO/REAL) system
25). Since 1998, all histologic diagnoses 
have  been  performed  using  the  WHO/REAL  classification.
The  ASCT  protocol  was  approved  by  the  institutional  review 
board  of  Asan  Medical  Center.  Written  informed  consent  was 
obtained  from  each  patient. 
Peripheral  blood  progenitor  cell  mobilization
In patients assessed as candidates for ASCT, peripheral blood 
progenitor  cell  (PBPC)  mobilization  and  collection  were 
performed as described previously
26). PBPCs were mobilized with 
chemotherapy,  followed  by  lenograstim  (Neutrogin,  Choongwae 
Ltd.,  Seoul,  Korea),  both  to  reduce  the  tumor  burden  and  to 
facilitate  PBPC  harvesting.  The  chemotherapy  regimens  for 
mobilization  were  4 g/m
2  cyclophosphamide  or  ESHAP 
(etoposide,  methylprednisolone,  cytarabine,  cisplatin),  with  or 
without  rituximab.  All  patients  received  10 μg/kg/day  lenogras-
tim  subcutaneously,  starting  on the  day after the  completion  of 
mobilization  chemotherapy  and  continuing  until  the  last  leuka-
pheresis procedure. PBPCs were collected with a continuous-flow 
blood  cell  separator  (Fenwal  CS3000  plus,  Baxter  Healthcare, 
D e e r f i e l d ,  I L ,  U S A ) .  T h e  t o t a l  C D 3 4
+  cell  count  was  monitored 
daily  following  each  collection,  with  the  target  amount  being 
5×10
6 CD34
+  cells  per  kilogram  patient  weight.
IPI  and  age-adjusted  IPI  at  ASCT
The IPI consists of five risk factors: age older than 60 years, 
LDH greater than the upper limit of normal, ECOG performance 
status greater than 1, stage III or IV disease, and more than one 
EN site. The age-adjusted IPI (AAIPI) consists of three of the IPI 
risk  factors:  LDH,  stage,  and  ECOG  performance  status
13).
ASCT  procedure
The  BEAM
15)  or  BEAC
3)  regimen  was  used  as  a  high-dose 
conditioning  regimen,  and  lenograstim  was  used  to  facilitate 
engraftment.  Patients  were  cared  for  in  a  single  room,  with 
reverse  isolation  strictly  maintained  to  prevent  infectious  com-
plications. All  patients were administered prophylactic  antimicro-
bials,  consisting  of  ciprofloxacin,  fluconazole,  and  acyclovir. 
Patients received transfusions of red blood cells and platelets as 
clinically  indicated.  Generally,  platelets  were  single  donor 
transfusions,  administered  to  keep  the  platelet  count  above 
20,000/mm
3 o r  t o  r e l i e v e  c l i n i c a l  b l e e d i n g .
Statistical  analysis
All  continuous  variables  were  analyzed  using  the  Mann- 
Whitney  test.  Proportions  were  compared  using  the  χ
2 t e s t  o r  
Fisher’s  exact  test,  as  appropriate.  Overall  survival  (OS)  was 
defined as the time from the date of transplantation until death 
or  the  last  follow-up.  Event-free  survival  (EFS)  was  measured 
from  the date  of  ASCT  until  the time of  a  relapse,  evidence  of 
disease progression, or death, regardless of cause. The date of 
the first event was used in calculating EFS. Survival curves were 
plotted using the product-limit method, according to Kaplan and 
M e i e r ,  a n d  w e r e  c o m p a r e d  u s i n g  t h e  l o g - r a n k  t e s t .  T h e  C o x  
proportional hazards regression model was used for multivariate 
analysis.  Statistical  analysis  was  performed  with  SPSS  (version 
1 2 . 0  f o r  W i n d o w s ,  S P S S  I n c . ,  C h i c a g o ,  I L ,  U S A )  a n d  t h e  
significance  level  was  set  at  0.05.The  Korean  Journal  of  Internal  Medicine:  Vol.  23,  No.  4,  December  2008 184
Characteristic
No  residual  EN 
involvement  (n=13)
1  or  more  residual  EN 
involvement  (n=14)
p
Age,  year
  M e d i a n  ( r a n g e )
Sex
  M a l e
  F e m a l e
First  line  chemotherapy
    CHOP
  R - C H O P
  O t h e r s
Second  line  chemotherapy
  E S H A P / D H A P
    R-ESHAP/R-DHAP
  O t h e r s
Radiotherapy  prior  to  mobilization
  N o t  p e r f o r m e d
    Performed
Disease  status
  I n i t i a l  p a r t i a l  r e s p o n s e
  S e n s i t i v e  r e l a p s e
  R e f r a c t o r y
Age  categorized
    60  years  or  younger
    Over  60  years
LDH  categorized
  N o r m a l  
  A b o v e  n o r m a l
Performance  categorized
  0 - 1
  2 - 4
Stage  categorized
  I ,  I I
  I I I ,  I V
EN  categorized
  0 - 1
  > 1
IPI
    Low/  Low-intermediate
    High-intermediate/  High
AAIPI
    Low/  Low-intermediate
    High-intermediate/High
37  (15-65)
10
3
10
2
1
3
5
3
3
10
3
9
1
11
2
8
5
13
0
11
2
13
0
12
1
12
1
51  (18-64)
7
7
9
1
4
3
2
5
4
10
3
4
7
11
3
2
12
11
3
1
13
8
6
7
7
4
10
NS
NS
NS
NS
NS
NS
NS
0.018
NS
<0.001
0.007
0.033
0.001
EN,  extranodal;  NS,  not  significant;  R,  Rituximab;  LDH,  Lactate  dehydrogenase;  IPI,  International  Prognostic  Index;  AAIPI, 
Age-adjusted  International  Prognostic  Index
Table  1.  Patient  characteristics  at  autologous  stem  cell  transplantation
RESULTS
Patient  characteristics
Twenty-seven  patients  with  DLBCL  were  eligible  for  this 
analysis. Of them, 13 (48%) had no residual EN involvement and 
14  (52%)  had  one  or  more  residual  EN  disease  at  ASCT. 
Characteristics  of  the  groups  of  patients  at  ASCT  are  listed  in 
Table 1. Age and gender were not different between the groups. 
The most frequent first-line chemotherapy regimens were CHOP 
and  rituximab  plus  CHOP.  Dose-intense  regimens,  such  as 
ESHAP, DHAP, and ICE, were administered to one patient in the 
n o - E N  g r o u p  a n d  f o u r  p a t i e n t s  i n  t h e  r e s i d u a l - E N  g r o u p ,  w h o  
were  found  to  have  a  significant  tumor  burden  and  poor 
prognostic  features  by  their  treating  physicians.  First-line 
chemotherapy  regimens  showed  no  statistically  significant 
difference  between  the  groups.  For  salvage  regimens,  ESHAP, 
DHAP,  rituximab  plus  ESHAP,  or  rituximab  plus  DHAP  were 
administered to the majority of patients. Three patients from the 
no-EN group and five patients from the residual-EN group were 
given  aggressive  regimens,  such  as  CODOX-M/IVAC  and Ock  Bae  Ko,  et  al.  ASCT  for  DLBCL  with  residual  EN 185
No.  of  involved  extranodal  sites  per  case 1 2 3 Total
Lung  &  pleura
Stomach
H e a d  &  n e c k
Intestine
*
Liver
Bone  marrow
Skin
Breast
Bone
Abdominal  organ  other  than  GIT  or  liver
**
3
2
1
1
1
2
2
1
1
1
1
1
1
1
1
1
6
3
3
2
2
1
1
1
1
1
Sites/Cases 8/8 10/5 3/1 21/14
GIT,  Gastrointestinal  tract
*E N  s i t e s  o f  I n t e s t i n e  w e r e  d u o d e n u m  a n d  i l u e m .  T h e y  w e r e  d i a g n o sed  by  endoscopic  biopsies.
**E N  s i t e  o f  o t h e r  a b d o m i n a l  o r g a n  w a s  a d r e n a l  g l a n d .  W i t h o u t  p a t hologic  confirm,  it  was  possible  to  diagnose  according  to  the 
radiologic  finding.
Table  2.  Distribution  of  extranodal  involvement  sites
Prognostic  factors %  survival  at  2  years  (95%  CI) p  value
Overall  survival
    Disease  status  (sensitive  vs  refractory)
    LDH  (normal  vs  above  normal)
    Performance  (0-1  vs  >1)
    Extranodal  involvement  (0  vs  1  or  more)
Event-free  survival
    Disease  status  (sensitive  vs  refractory)
    LDH  (normal  vs  above  normal)
    Performance  (0-1  vs  >1)
    Extranodal  involvement  (0  vs  1  or  more)
38  (16-60)  vs  13  (0-36)
83  (60-100)  vs  12  (0-27)
35  (16-54)  vs  0
64  (38-90)  vs  14  (0-32)
45  (23-67)  vs  13  (0-36)
9 0  ( 7 1 - 1 0 0 )  v s  6  ( 0 - 1 7 )
40  (20-60)  vs  0
62  (37-87)  vs  14  (0-32)
0.039
<0.001
<0.001
0.021
0.019
<0.001
<0.001
0.020
LDH,  Lactate  dehydrogenase
Table  3.  Prognostic  factors  at  autologous  stem  cell  transplantation  in  univariate  analysis
GMALL, chosen by the treating physician. Two patients from the 
no-EN group and four patients from the residual-EN group were 
not  administered  second-line  salvage  chemotherapy  because  of 
their  initial  partial  response  (PR)  status,  and  their  PBPCs  were 
mobilized  by  high-dose  cyclophosphamide.  Salvage  chemo-
therapy  regimens  showed  no  difference  between  the  groups. 
Radiotherapy  history  and  disease  status  at  ASCT  were  not 
different  between  the  groups.  Among  the  IPI  factors,  age  and 
performance  status  were  not  significantly  different  between  the 
g r o u p s .  P a t i e n t s  s h o w i n g  L D H  a b o v e  t h e  n o r m a l  r a n g e  w e r e  
more frequent in the residual-EN group (86%) than in the no-EN 
group  (39%;  p=0.018).  Advanced  stage  III/IV  disease  was 
o b s e r v e d  i n  1 3  p a t i e n t s  ( 9 3 % )  i n  t h e  r e s i d u a l - E N  g r o u p  ( 9 3 % )  
and  in  one  patient  (15%)  in  the  no-EN  group  (p <  0 . 0 0 1 ) .  E N  
involvement  score,  categorized  by  the  IPI  system,  was 
significantly  worse  in  the  residual-EN  group  than  in  the  no-EN 
group (p=0.007). The IPI score was high-intermediate or high in 
seven patients (50%) in the residual-EN group and in one patient 
(8%)  in  the  no-EN  group  (p=0.033).  Ten  patients  (71%)  in  the 
residual-EN  group  had  high-intermediate  or  high  AAIPI  scores 
and  12  patients  (92%)  in  the  no  EN  group  showed  low  or 
low-intermediate  risk  (p=0.001).
Details of the distribution of EN involvement sites at ASCT are 
presented in Table 2. Eight patients had involvement of one EN 
s i t e ,  f i v e  h a d  i n v o l v e m e n t  o f  t w o  E N  s i t e s ,  a n d  o n e  h a d  
involvement of three EN sites. Of the 21 total EN sites in these 
14  patients  with  residual  EN  disease  at  ASCT,  the  most 
frequently observed were the lung and pleura (6 sites), followed 
by  the  stomach  (3  sites),  head  and  neck  (3  sites),  intestine  (2 
sites),  and  liver  (2  sites). 
Response  to  ASCT
Because  no  ASCT-related  mortality  occurred  in  the  27 
patients,  all were evaluable for response. Twelve  patients (44%) 
achieved  a  complete  response  (CR)  post-ASCT,  seven  patients 
(26%)  a  PR,  and  eight  patients  (30%)  failed.  Of  19  patients 
transplanted  in  chemosensitive  status,  11  (58%)  achieved  CR 
w i t h  t h e  A S C T .  H o w e v e r ,  o n l y  o n e  p a t i e n t  ( 1 3 % )  o f  t h e  e i g h t  
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Figure 1. Overall survival and event-free survival for all 27 patients. The
Kaplan-Meier  curves  show  that  the  overall  survival  2  years  after 
autologous  stem  cell  transplantation  was  37%  and  the  proportion o f  
patients  remaining  event-free  at  2  years  was  36%.
 
Figure 2. Overall survival according to extranodal (EN) disease status at autologous stem cell transplantation. (A) Comparison between 0-1 EN site
and  more  than 1  E N  s i t e  s h o w e d  n o  d i f f e r e n c e  i n  o v e r a l l  s u r v i v a l .  ( B )  M o d i f i e d  categorization:  patients  with  no  remaining  EN  site  had  a  2-year 
overall  survival  rate  of  64%,  significantly  better  than  the  14%  rate  observed  in  patients  with  remaining  EN  site(s)  at  autologous  stem  cell 
transplantation.
Survival
The  median  follow-up  duration  for  survivors  was  24  months 
(range, 7-36). Eighteen patients (67%) have died and nine patients 
are  alive.  Twelve  patients  died  of  disease  progression  and  six 
patients  died  of  other  illnesses.  No  occurrence  of  secondary 
n e o p l a s m  w a s  o b s e r v e d .  T h e  K a p l a n - M e i e r  e s t i m a t e  o f  t h e  
proportion  of  patients  remaining  alive  at  2  years  following  ASCT 
w a s  3 7 % ,  w i t h  a n  e s t i m a t e d EF S a t  2 y e a r s  of  36% ( Fi gu r e 1).
Predictors  of  outcome  following  ASCT
The univariate analysis for OS and EFS is shown in Table 3. 
A  better  outcome  was  associated  with  chemosensitive  disease 
status  at  ASCT,  normal  LDH  level,  good  performance,  and  no 
E N  i n v o l v e m e n t  a t  A S C T .  H o w e v e r ,  b a s e d  o n  a  m u l t i v a r i a t e  
analysis,  only  normal  LDH  level  [hazard  ratio  (HR)  0.05;  95% 
confidence interval (CI) 0.01-0.39; p=0.004 for OS; and HR 0.04; 
95%  CI  0.01-0.35;  p=0.003  for  EFS]  was  associated  with 
superior  survival.
EN  involvement  as  a  predictor  of  outcome  following  ASCT
Note that when categorized according to the original IPI, the 
2-year OS was 37% for patients with 0-1 EN sites and 33% for 
t h o s e  w i t h  m o r e  t h a n  1  E N  i n v o l v e me n t  a t  A S C T  ( p=0.874;
AB
p=0.874 p=0.021 
Figure 3. E ve n t- fre e  s u rv iv a l a c c o rdin g  to  e x tra n o d a l (E N ) dis e a s e  sta tus  at  autologous  stem  cell  transplantation.  (A)  Comparison  betwee n  0 - 1  E N
s i t e  a n d  m o r e  t h a n  1  EN  site  showed  no  difference  in  event-free  survival.  (B)  Modif i e d  c a t e g o r i z a t i o n :  p a t i e n t s  w i t h  n o  r e m a i n i n g  E N  s i t e  h a d  a  
2-year event-free survival rate of 62%, significantly better than the 14% rate observed in patients with remaining EN site(s) at autologous stem cell
transplantation.
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Figure 2A). When we applied a modified categorization of EN 
involvement, grouped as negative or positive, the 2-year OS was 
64%  for  patients  with  no  EN  site  at  ASCT,  significantly  better 
than  the  14%  2-year  OS  in  patients  with  EN  involvement  at 
ASCT  (p=0.021;  Figure 2 B ) .  T h e  2 - y e a r  E F S  w a s  3 6 %  f o r  
patients  with  0-1  EN  site  and  33%  with  more  than  1  EN 
involvement  at  ASCT  (p=0.893;  Figure 3A).  With  the  modified 
categorization  of  EN  involvement,  the  2-year  EFS  was  62%  for 
patients  with  no  residual  EN  site  at  ASCT,  significantly  better 
t h a n  t h e  1 4 %  2 - y e a r  E F S  i n  p a t i e n t s  w i t h  r e s i d u a l  E N  
involvement  at  ASCT  (p=0.02;  Figure 3B).
DISCUSSION
Patients  with  DLBCL  can  be  cured  by  anthracycline-based 
chemotherapy.  The  recent  introduction  of  rituximab  and  dose- 
dense  chemotherapies  has  improved  survival  in  these  patients
27, 28). 
However, at least 50% of patients with DLBCL fail to achieve a 
C R ,  o r  r e l a p s e  a f t e r  C R .  H a l f  o f  t h e  r e l a p s i n g  o r  r e f r a c t o r y  
patients respond to salvage chemotherapy, but cure is expected 
in  fewer  than  10%.  Eventually,  almost  50%  of  patients  with 
DLBCL  die  of  their  disease
29).  High-dose  therapy  followed  by 
ASCT has been widely used to improve the prognosis in these 
patients  and  has  prolonged  survival,  especially  in  those  with 
chemosensitive  disease.
Over  the  past  10  years,  ASCT  for  DLBCL  performed  at  our 
institution  resulted in  poor  outcomes  for  patients  who were  not 
in CR at ASCT, with a 37% rate of 2-year OS, and a 36% rate 
of 2-year EFS. The poor outcomes we observed may have been 
due to the possibly unique biology of DLBCL in Koreans or other 
unknown  factors.  We  sought  to  discover  factors  predicting 
prognosis  of  these  patients  with  residual  disease  at  ASCT, 
especially focusing on the influence of EN involvement. Thus, all 
patients had to have had residual disease at the time of ASCT 
to join this study. When this condition was met, we included any 
patients  with  DLBCL  for  whom  ASCT  had  been  performed  at 
our  institution.
In the current study, disease status at the time of ASCT was 
a  significant  factor  predicting  OS  and  EFS.  Among  the  five  IPI 
factors, LDH and performance status had statistical  significance 
as  predictors  for  OS  and  EFS.  Age  and  stage  showed  no 
significance, although that may have been the result of our small 
sample  size.  EN  involvement  categorized  by  the  original  IPI 
system  did  not  show  a  survival  difference.
Our initial expectation with this retrospective analysis was that 
EN  involvement  may  have  a  significant  prognostic  value.  While 
EN lymphomas represent 30～40% of all lymphoid neoplasms in 
Western  countries,  around  two-thirds  of  Korean  NHLs  are 
classified  as  extranodal
20).  This  high  frequency  of  EN  involve-
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ment  may  be  associated  with  poorer  survival  rates  in  Korean 
patients. Fourteen of 27 patients (52%) in the current study had 
residual  EN  disease,  even  at  ASCT.  A  univariate  analysis, 
however, showed no significant difference between patients with 
0-1 EN site and those with more than 1 EN sites based on the 
IPI  system.  When  patients  were  stratified  into  those  with  or 
w i t h o u t  r e s i d u a l  E N  s i t e s  a t  t h e  t i m e  o f  A S C T ,  a  s t a t i s t i c a l l y  
significant  difference  was  observed  in  the  2-year  OS  (14%  vs. 
6 4 % )  a n d  2 - y e a r  E F S  ( 1 4 %  v s .  6 2 % ) .
A l m o s t  a l l  r e p o r t s  d e a l i n g  w i t h  t h e  c l i n i c a l  c o u r s e  a n d  
outcome following ASCT in NHL have classified EN involvement 
as 0-1 versus more than 1 site, as in the original IPI system. In 
a study categorizing EN disease as 0 versus 1 or more sites, a 
statistically significant difference in the 5-year OS (p=0.004) was 
detected
30).  N o t e  t h a t  w h i l e  t h e y  u s e d  a  d i f f e r e n t  c a t e g o r i z a t i o n  
from the original IPI system, they did not provide an explanation 
f o r  t h i s .  T h e y  a n a l y z e d  1 1 4  p a t i e n t s  w i t h  D L B C L  w h o  d i d  n o t  
achieve  CR  after  induction  chemotherapy  and  were  set  to  be 
treated  with  ASCT.  Seventy-one  patients  (62%)  had  EN 
involvement at diagnosis and 39 patients (35%) had residual EN 
disease  at  ASCT.  The  5-year  OS  was  52%  in  patients  with  no 
residual  EN  disease,  significantly  better  than  the  25%  for  the 
5-year  OS  in  patients  with  residual  EN  involvement.  Age- 
adjusted IPI, EN disease (0 versus >1) and disease status were 
significant  prognostic  factors  for  overall  survival  in  a  univariate 
analysis  in  that  report. 
Considering both the report from the GEL/TAMO group
30)  and 
the  results  of  the  current  study,  categorization  into  negative 
versus  positive  EN  involvement  had  predictive  value.  Patients 
w i t h  D L B C L  a n d  r e s i d u a l  E N  d i s e a s e  a t  A S C T  d i d  p o o r l y  
compared  to  those  with  no  residual  EN  involvement.  This 
categorization may be valid especially when the EN involvement 
is more prevalent. In the current study, EN involvement at ASCT 
categorized  as  absent  or  present  showed  a  strong  association 
with predictors of poor prognosis, such as LDH above a normal 
range,  advanced  stage,  higher  IPI,  and  higher  AAIPI  at  ASCT. 
Why  patients  with  residual  EN  disease  at  ASCT  have  poor 
survival  remains  to  be  answered. 
Patients  with  DLBCL  and  residual  EN  disease  at  ASCT  may 
h a v e  p o o r  s u r v i v a l  w i t h  A S C T  a n d  s h o u l d  b e  g i v e n  o t h e r  n o v e l  
therapies.  Because  this  was  a  retrospective  study  performed 
w i t h  a  l i m i t e d  n u m b e r  o f  p a t i e n t s ,  t h e  r e s u l t s  s h o u l d  b e  
interpreted  cautiously.  A  small  sample  size  and  short  follow-up 
period  cause  limitations  in  statistical  power.
In conclusion, Korean patients with DLBCL and residual disease 
at ASCT have frequent EN involvement, and patients with residual 
E N  i n v ol v e m e n t  s h ow  po or  ou t c ome s  f ol l ow i n g A S C T .  A  m od i f i e d 
categorization of EN involvement into negative versus positive may 
be more useful in predicting outcome following ASCT, especially 
when  EN  disease  is  prevalent.
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